Johnson & Johnson: Health Canada authorizes Lazcluze/Rybrevant combo
Johnson & Johnson announced that Health Canada has issued a Notice of Compliance for Lazcluze in combination with Rybrevant for the ...
Johnson & Johnson announces new icotrokinra data from Phase 3 program
Johnson & Johnson announced new icotrokinra, JNJ-2113, data from its comprehensive Phase 3 clinical program and the start of the first-ever ...
North American Morning Briefing: Stock Futures -2-
WASHINGTON-Republicans are charging ahead with a proposal endorsed by President Trump that would keep the government funded into the fall while reducing spending, setting up a clash with Democrats ...